| Trial ID: | L0261 |
| Source ID: | NCT04773964
|
| Associated Drug: |
MET642
|
| Title: |
Study to Evaluate MET642 in Patients With NASH
|
| Acronym: |
--
|
| Status: |
Active, not recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
NASH - Nonalcoholic Steatohepatitis
|
| Interventions: |
Drug: MET642|Drug: Placebo
|
| Outcome Measures: |
Adverse Events|Vital Signs|Laboratory tests|ECG|Pharmacokinetic Profile of MET642|Pharmacodynamic Profile of MET642|Pharmacological Activity of MET642
|
| Sponsor/Collaborators: |
Metacrine, Inc.
|
| Gender: |
All
|
| Age: |
18 Years to 75 Years ?? (Adult, Older Adult)
|
| Phases: |
Phase 2
|
| Enrollment: |
215
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
|
| Start Date: |
March 3, 2021
|
| Completion Date: |
February 14, 2022
|
| Results First Posted: |
--
|
| Last Update Posted: |
September 20, 2021
|
| Locations: |
Pinnacle Research, San Antonio, Texas, United States
|
| URL: |
https://ClinicalTrials.gov/show/NCT04773964
|
